


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T14:04:17Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12406534" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12406534</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>pedirheum</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pediatr Rheumatol Online J</journal-id><journal-id journal-id-type="iso-abbrev">Pediatr Rheumatol Online J</journal-id><journal-id journal-id-type="pmc-domain-id">492</journal-id><journal-id journal-id-type="pmc-domain">pedirheum</journal-id><journal-title-group><journal-title>Pediatric Rheumatology</journal-title></journal-title-group><issn pub-type="epub">1546-0096</issn><publisher><publisher-name>BMC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12406534</article-id><article-id pub-id-type="pmcid-ver">PMC12406534.1</article-id><article-id pub-id-type="pmcaid">12406534</article-id><article-id pub-id-type="pmcaiid">12406534</article-id><article-id pub-id-type="pmid">40898345</article-id><article-id pub-id-type="doi">10.1186/s12969-025-01140-0</article-id><article-id pub-id-type="publisher-id">1140</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Evaluating the causal effect of circulating proteome on the risk of Juvenile idiopathic arthritis: an omics pipeline study</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Wu</surname><given-names initials="X">Xinglin</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Luo</surname><given-names initials="Q">Qiang</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Luo</surname><given-names initials="X">Xiwen</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Liu</surname><given-names initials="D">Dawei</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="F">Fengming</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ma</surname><given-names initials="C">Chenxi</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Tang</surname><given-names initials="X">Xuemei</given-names></name><address><email>tangxuemei2008@163.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05pz4ws32</institution-id><institution-id institution-id-type="GRID">grid.488412.3</institution-id><institution>Department of Rheumatology and Immunology, </institution><institution>Children&#8217;s Hospital of Chongqing Medical University, </institution></institution-wrap>No. 136, Zhongshan 2nd Road, Yuzhong District, Chongqing, 400014 China </aff><aff id="Aff2"><label>2</label>Chongqing Key Laboratory of Child Infection and Immunity, Chongqing, 400014 China </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01mv9t934</institution-id><institution-id institution-id-type="GRID">grid.419897.a</institution-id><institution-id institution-id-type="ISNI">0000 0004 0369 313X</institution-id><institution>Department of Pediatric Research Institute, </institution><institution>Ministry of Education Key Laboratory of Child Development and Disorders, </institution></institution-wrap>Chongqing, 400014 China </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05pz4ws32</institution-id><institution-id institution-id-type="GRID">grid.488412.3</institution-id><institution>National Clinical Research Center for Child Health and Disorders, </institution></institution-wrap>Chongqing, 400014 China </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00bsdxt65</institution-id><institution-id institution-id-type="GRID">grid.507984.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 1764 2990</institution-id><institution>China International Science and Technology Cooperation Base of Child Development and Critical Disorders, </institution></institution-wrap>Chongqing, 400014 China </aff></contrib-group><pub-date pub-type="epub"><day>2</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>23</volume><issue-id pub-id-type="pmc-issue-id">478337</issue-id><elocation-id>91</elocation-id><history><date date-type="received"><day>23</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>5</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 10:25:45.023"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="12969_2025_Article_1140.pdf"/><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Genome-wide association studies (GWAS) have pinpointed a multitude of risk loci associated with Juvenile Idiopathic Arthritis (JIA), but it is challenging to decipher novel plasma proteins. To address this, we applied an integrative omics pipeline to uncover novel proteins associated with JIA risk.</p></sec><sec><title>Methods</title><p id="Par2">In this research, we utilized an integrative omics method to identify new plasma proteins associated with JIA. Complementary results from an independent cohort were analyzed through Whole Genome Sequencing (WGS), single-cell RNA sequencing (scRNA-seq), and bulk RNA sequencing (bulk RNA-seq) at the Children's Hospital of Chongqing Medical University to validate the reliability of the identified novel proteins. Additionally, to assess the therapeutic potential of novel proteins, we performed Phe-WAS and conducted an extensive review of existing literature using PubMed and Web of Science.</p></sec><sec><title>Results</title><p id="Par3">An integrative omics pipeline analysis identified ERAP2 as having putatively causal effects on JIA. In the fourth step of Summary-data-based Mendelian randomization analysis, we discovered that the SNP rs2927608 and rs2910686 can regulate the expression of the ERAP2 gene, thereby regulating the protein content of both ERAP2 and ERAP1. WGS analysis also detected two potentially pathogenic mutations on ERAP2 in sJIA patients. ScRNA-seq reveals that ERAP2 expression is significantly elevated in patients with sJIA compared to normal and other subtypes, particularly in monocytes. Bulk RNA-seq with ROC analysis demonstrating significant diagnostic power (AUC&#8201;=&#8201;0.86, 95%CI: 0.71&#8211;1.00) in discriminating sJIA from healthy controls. Literature and Phe-WAS search revealed that ERAP2 is primarily studied in the context of genetic predisposition to disease and is closely related to autoimmune disorders.</p></sec><sec><title>Conclusions</title><p id="Par4">ERAP2 was identified as a candidate associated with JIA, especially sJIA, through integrative omics analysis, indicating its potential role in protein-mediated disease mechanisms and therapeutic targeting.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s12969-025-01140-0.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Juvenile idiopathic arthritis</kwd><kwd>Integrative Omics Pipeline</kwd><kwd>Whole Genome Sequencing</kwd><kwd>ScRNA-seq</kwd><kwd>Literature review</kwd><kwd>Phenome-wide association study</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100012166</institution-id><institution>National Key Research and Development Program of China</institution></institution-wrap></funding-source><award-id>No. 2021YFC2702003</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par43">Juvenile idiopathic arthritis (JIA) represents a critical autoimmune disorder that causes persistent joint inflammation and stands as a leading cause of disability among children under 16&#160;years [<xref ref-type="bibr" rid="CR1">1</xref>&#8211;<xref ref-type="bibr" rid="CR3">3</xref>]. According to a systematic review conducted in 2014, the incidence of JIA varies from 1.6 to 23 cases per 100,000 and with a prevalence ranging from 3.8 to 400 per 100,000 individuals across Europe [<xref ref-type="bibr" rid="CR4">4</xref>]. Beyond its immediate effects on joint health, JIA can lead to complications affecting the spine, eyes, kidneys, and lungs, which in turn diminish mobility and add to the overall health burden [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. Moreover, the disease not only deteriorates the quality of life for affected youths but also imposes substantial economic demands on their families and the broader community [<xref ref-type="bibr" rid="CR7">7</xref>].</p><p id="Par44">As an inflammation-associated condition, treatment for JIA typically starts with non-steroidal anti-inflammatory drugs (NSAIDs) and/or intra-articular corticosteroid injections, as well as second-line traditional synthetic disease-modifying anti-rheumatic drugs (tsDMARDs) or biological DMARDs [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. Moreover, due to the adverse reactions of medications and the relatively singular action targets, the treatment outcomes for some JIA patients are not optimistic [<xref ref-type="bibr" rid="CR10">10</xref>]. And, due to the complexity of JIA's pathogenesis, still largely unexplored, has impeded the development of effective treatments. Therefore, exploring the potential mechanism and drug targets of JIA is of great value.</p><p id="Par45">Recent technological advancements in transcriptomic and proteomic profiling have granted unparalleled access to both tissue-specific and circulating gene products, vital for understanding both disease mechanisms and health. Nevertheless, observational studies that directly correlate gene transcripts or protein levels with phenotypic outcomes can encounter issues like confounding or reverse causation [<xref ref-type="bibr" rid="CR11">11</xref>]. By integrating genetic data with transcripts, proteins, and phenotypes, it becomes possible to identify specific biomarkers as likely causal agents of diseases [<xref ref-type="bibr" rid="CR12">12</xref>]. For instance, Gusev et al. employed cis-acting single-nucleotide polymorphisms (SNPs) to genetically infer transcript levels and integrate them with Genome-Wide Association Studies (GWAS) summary statistics to establish causality, a method known as transcriptome-wide association study (TWAS) [<xref ref-type="bibr" rid="CR13">13</xref>]. Our team has adapted this strategy to proteome-wide association studies (PWAS), utilizing genetically imputed models of the plasma proteome combined with transcriptomic data to investigate prospective drug targets for JIA [<xref ref-type="bibr" rid="CR14">14</xref>]. These techniques, TWAS and PWAS, function as instrumental variable analyses similar to two-sample Mendelian randomization (MR) [<xref ref-type="bibr" rid="CR15">15</xref>], using genetic models confined to the cis-regions of genes, thus minimizing confounding by horizontal pleiotropy. This approach is further refined by colocalization analyses that consider multiple causal variants within the same genomic region, effectively reducing genetic confounding from linkage disequilibrium [<xref ref-type="bibr" rid="CR16">16</xref>&#8211;<xref ref-type="bibr" rid="CR18">18</xref>].</p><p id="Par46">In this investigation, we implemented an omics pipeline analysis aimed at identifying promising drug targets for JIA and potential therapeutic targets for MS, as illustrated in Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>. Initially, we applied omics pipeline analysis techniques to pinpoint potential causal factors in plasma for JIA, based on GWAS data. Subsequently, we corroborated our initial findings through Bayesian co-localization analysis. Further exploration of endoplasmic reticulum aminopeptidase 2 (ERAP2) potential as a therapeutic target was pursued through literature review and phenome-wide association study (Phe-WAS). To solidify our findings, we performed external validation using data from an independent cohort at Children's Hospital of Chongqing Medical University.<fig id="Fig1" position="float" orientation="portrait"><label>Fig.&#160;1</label><caption><p>Workfow of integrative omics pipeline of Juvenile idiopathic arthritis</p></caption><graphic id="MO1" position="float" orientation="portrait" xlink:href="12969_2025_1140_Fig1_HTML.jpg"/></fig></p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Study design and data resources</title><p id="Par47">For this analysis, we accessed the most recent GWAS summary statistics for JIA from the GWAS catalog, utilizing dataset catalog ID: GCST90010715 [<xref ref-type="bibr" rid="CR19">19</xref>], including 6.3 million SNPs with MAF&#8201;&#8805;&#8201;1%. Summary statistics were processed using LD Score Regression (LDSC) software.</p></sec><sec id="Sec4"><title>Heritability analysis and partitioned heritability</title><p id="Par48">Heritability was estimated using LDSC with precomputed LD scores from the 1000 Genomes Project (European ancestry, HapMap3 SNP set). In additional, we performed partitioned heritability analysis using stratified LDSC (S-LDSC), examining enrichment across functional genomic categories (coding regions, conserved regions, DNase I digital genomic foot-printing (DGF) regions, DNase I hypersensitive sites (DHSs), fetal DHSs, intronic regions, promoters, repressed regions, super-enhancers, transcribed regions, and key histone marks including H3K27ac, H3K4me1, H3K4me3, and H3K9ac).</p></sec><sec id="Sec5"><title>Tissue specific enrichment of SNP heritability</title><p id="Par49">We assessed tissue-specific SNP heritability enrichment using GTEx-based S-LDSC across 53 tissues [<xref ref-type="bibr" rid="CR20">20</xref>]. To validate findings, we used MAGMA to conduct gene-set and tissue enrichment analyses based on GWAS summary statistics and GTEx v8 gene expression data [<xref ref-type="bibr" rid="CR21">21</xref>].</p></sec><sec id="Sec6"><title>Proteome-wide association studies</title><p id="Par50">We used the FUSION tool to perform PWAS [<xref ref-type="bibr" rid="CR22">22</xref>], which estimates SNP effects on protein levels using multiple predictive models (top1, BLUP, lasso, enet, and bslmm). The model with the best predictive performance was selected to compute protein weights for JIA. These weights were combined with GWAS z-scores through a weighted linear sum across independent SNPs to generate PWAS results.</p><p id="Par51">In the discovery phase of our study, protein weights were derived from the European ancestry subpopulation data within the Atherosclerosis Risk in Communities (ARIC) study (available at <ext-link ext-link-type="uri" xlink:href="http://nilanjanchatterjeelab.org/pwas/">http://nilanjanchatterjeelab.org/pwas/</ext-link>). For the replication datasets, we utilized weights provided by Mancuso Lab (accessible at <ext-link ext-link-type="uri" xlink:href="https://www.mancusolab.com/pwas">https://www.mancusolab.com/pwas</ext-link>). To address the concern of multiple testing inherent in our analysis, we implemented a Bonferroni correction to adjust the <italic toggle="yes">P</italic>-values, thereby enhancing the statistical rigor and reliability of our results.</p></sec><sec id="Sec7"><title>Transcriptome&#8209;wide association studies</title><p id="Par52">We performed TWAS using the FUSION framework [<xref ref-type="bibr" rid="CR13">13</xref>], applying gene expression weights from JIA-relevant tissues. Multiple predictive models (top1, BLUP, lasso, enet, and bslmm) were used, with LD reference from the European cohort of the 1000 Genomes Project. This enabled a comprehensive assessment of gene expression effects on JIA risk.</p><p id="Par53">In the discovery phase of our study, the weights for the datasets were derived from the European ancestry subpopulation of GTEx V8 (<ext-link ext-link-type="uri" xlink:href="http://gusevlab.org/projects/fusion">http://gusevlab.org/projects/fusion</ext-link>). For the replication datasets, we used weights from the Netherlands Twin Register (NTR) and the Young Finns Study (YFS) (<ext-link ext-link-type="uri" xlink:href="http://gusevlab.org/projects/fusion">http://gusevlab.org/projects/fusion</ext-link>). To address the potential for multiple testing errors, we implemented a Bonferroni correction to adjust the <italic toggle="yes">P</italic>-values, ensuring the robustness and reliability of our statistical analyses.</p></sec><sec id="Sec8"><title>Cross-tissue transcriptome-wide association analysis</title><p id="Par54">Since gene functions vary across tissues, single-tissue analysis may miss important regulatory effects. To gain a more comprehensive view of JIA-related mechanisms, we integrated GWAS summary statistics with eQTL data to perform both single- and cross-tissue enrichment analyses [<xref ref-type="bibr" rid="CR23">23</xref>]. This approach helps elucidate the complex genetic architecture underlying JIA.</p></sec><sec id="Sec9"><title>Colocalization analysis</title><p id="Par55">We used the coloc R package to assess whether PWAS/TWAS signals and GWAS associations colocalize [<xref ref-type="bibr" rid="CR18">18</xref>]. Bayesian posterior probabilities were calculated for five hypotheses; a PPH4&#8201;&gt;&#8201;0.75 was considered strong evidence of colocalization.</p></sec><sec id="Sec10"><title>Summary-data-based Mendelian randomization</title><p id="Par56">To explore how SNPs may regulate potential drug targets and contribute to JIA, we performed Summary-data-based Mendelian Randomization (SMR) analysis [<xref ref-type="bibr" rid="CR24">24</xref>]. SMR integrates GWAS summary statistics with protein (pQTL) and expression (eQTL) QTL data to assess associations between gene expression and disease phenotypes. Genome-wide significant SNPs were used as instrumental variables. We also applied the HEIDI test to distinguish true causal effects from linkage or horizontal pleiotropy by evaluating effect heterogeneity across loci.</p><p id="Par57">In this study, we adopted a network SMR approach to identify and validate potential drug targets for JIA, aiming to provide a more nuanced understanding of the genetic underpinnings and potential intervention points for therapy.<list list-type="bullet"><list-item><p id="Par58">Step 1: To validate the potential drug targets at the protein level, we processed protein summary data files from ARIC/DECODE in accordance with the guidelines provided on the official SMR tool website. The data, initially available in Variant Call Format (VCF), were transformed into a format suitable for SMR analysis. This process involved generating three files (.besd,.bepi, and.besi) to represent the associations between SNPs and genes. Finally, pQTL analysis was conducted using the SMR files converted from ARIC to verify the aforementioned results.</p></list-item><list-item><p id="Par59">Step 2: In order to validate the aforementioned potential drug targets at the gene level, we utilized SMR files provided by GTEx V8 and eqtlgen to conduct eQTL analysis, further verifying the aforementioned results.</p></list-item><list-item><p id="Par60">Step 3: We conducted further meta-analyses on ARIC/decode as well as GTEx V8/eqtlgen to evaluate the impact of potential drug targets on JIA.</p></list-item><list-item><p id="Par61">Step 4: Involved utilizing SNPs as instrumental variables, with blood gene expressions serving as the exposure and blood protein expressions as the outcome. This step was crucial for evaluating the relationships between gene expression and protein expression in the blood. By examining these interactions, we could explore the mechanisms by which SNPs influence protein expression via the regulation of gene activity. This approach provided deeper insights into the genetic regulation of proteins, potentially elucidating pathways affected in diseases such as JIA.</p></list-item></list></p></sec><sec id="Sec11"><title>Phenome-wide association study</title><p id="Par62">We conducted a Phe-WAS using the Open Targets Platform to delve deeper into candidate SNPs and other SNPs within the same LD block that may be associated with specific diseases [<xref ref-type="bibr" rid="CR25">25</xref>].</p></sec><sec id="Sec12"><title>scRNA-seq and WGS patient cohort</title><p id="Par63">In this research, we utilized Whole Genome Sequencing (WGS) and scRNA-seq to thoroughly investigate the molecular underpinnings of JIA. Initially, 54 (WGS) and 14 (scRNA-seq) newly diagnosed and untreated JIA patients from Children's Hospital of Chongqing Medical University in China. For detailed clinical information, please refer to Table S1 and S2. All participants were classified according to the International League of Associations for Rheumatology (ILAR) criteria (1). Ethical approval for the study was obtained from the Ethics Committee of the Children&#8217;s Hospital affiliated with Chongqing Medical University (2021 NO.21). For the scRNA-seq, we also included data from 3 control from the GEO database project <ext-link ext-link-type="pmc:entrez-geo" xlink:href="GSE168732">GSE168732</ext-link> and 1 normal from Children's Hospital of Chongqing Medical University.</p></sec><sec id="Sec13"><title>Identification of DEGs and their functional analysis in scRNA-seq</title><p id="Par64">Cells were clustered using standard pipelines. Differentially expressed genes (DEGs) were identified via Wilcoxon test. Pathway enrichment was performed using GSEABase, GSVA, and irGSEA, referencing the MSigDB gene sets.</p></sec><sec id="Sec14"><title>RNA-Seq data for Chongqing cohort</title><p id="Par65">PBMCs from 18 sJIA patients and 8 healthy controls were sequenced. RNA was extracted using TRIzol, quantified, and processed for stranded mRNA library preparation. Sequencing was performed using DNBSEQ-T7 (PE150). Reads were cleaned (Trimmomatic), aligned (STAR), and gene counts were obtained (featureCounts).</p></sec><sec id="Sec15"><title>Receiver Operating Characteristic (ROC) analysis</title><p id="Par66">To evaluate the predictive ability of ERAP2 expression for the risk of sJIA, we performed ROC curve analysis using the pROC package in R.</p></sec><sec id="Sec16"><title>Literature review in ERAP2</title><p id="Par67">The data for this review were collected using PubMed and web of science. The inclusion criteria were as follows: The inclusion criteria for selecting publications were as follows: a) The title must explicitly mention a relationship with ERAP2; b) The publication must be written in English. Subsequently, these articles were independently reviewed by two additional authors to ensure adherence to the inclusion criteria. The selected publications were further categorized based on their focus into four distinct areas: therapy, diagnostics, disease-related studies, and pharmacology. This classification was determined by the type of citation and the primary emphasis of each article.</p></sec><sec id="Sec17"><title>Druggability of identified targets</title><p id="Par68">Known drugs and tractability data for each gene were annotated using the Open Targets Platform [<xref ref-type="bibr" rid="CR25">25</xref>]. The approval status of these drugs was marked as"true"if there was at least one approved drug associated with a specific gene, indicating its regulatory acceptance for clinical use.</p></sec></sec><sec id="Sec18"><title>Result</title><sec id="Sec19"><title>Heritability analysis in Juvenile idiopathic arthritis</title><p id="Par69">In this study, we employed the LDSC method to explore the genetic factors involved in JIA. And LD score regression revealed an SNP heritability estimates for JIA of 0.105 (0.017), suggesting that genetic factors may influence the risk of JIA.</p><p id="Par70">To further elucidate the genetic mechanisms of JIA, we conducted a detailed analysis of the role of various genomic functional elements in the genetic association with JIA. By categorizing SNPs into different functional groups and calculating the LD scores within each category, we identified several genomic markers closely associated with the onset of JIA (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;5.154&#8201;&#215;&#8201;10<sup>&#8211;4</sup>). These include SuperEnhancer_HniszL2_0, CpG_Content_50kbL2_0, H3K27ac_HniszL2_0, TSS_HoffmanL2_0, Human_Promoter_VillarL2_0, and Repressed_HoffmanL2_0. These findings underscore the significance of these genomic elements in the genetic landscape of JIA (Table S3).</p><p id="Par71">Finally, we delved deeper into the role of tissue-specific factors in JIA by applying the S-LDSC method. Our analysis indicates that blood tissue may play a significant role in the pathogenesis of JIA. To corroborate the robustness of this finding, we also conducted tissue-specific enrichment and gene-set enrichment analyses using the MAGMA method. These analyses align with the conclusions drawn from the S-LDSC method, further emphasizing the potential role of blood tissue in JIA (Figs. S1 and S2).</p></sec><sec id="Sec20"><title>Search and validation of potential drug targets</title><p id="Par72">In the discovery datasets, PWAS analysis revealed a close association between 10 proteins and JIA, including C2, MICB, TNXB, HSPA1A, LMAN2L, ERAP2, NCR3, AIF1, ATF6B, and APOM at a Bonferroni significance level (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;3.72&#8201;&#215;&#8201;10<sup>&#8722;5</sup>) in ARIC (Table S4 and Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>A, B). To reduce genetic confounding, we performed Bayesian co-localization analyses, which strongly suggested that LMAN2L, ERAP2, NCR3, AIF1, APOM, and ATF6B shared the same variant with JIA (Table S4). In the replication datasets, AIF1, AGER, HLA-DQA2, NCR3, APOM, C4B_2, IL27, C4B, LST1, ERAP2, and APOM were also closely associated with JIA (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;4.84&#8201;&#215;&#8201;10<sup>&#8722;5</sup>) (Table S5 and Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>C, D). Intersection of discovery and replication datasets pinpointed ERAP2 as a potential drug target in JIA (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>E). And, bayesian co-localization only indicated that ERAP2 shared the same variant with JIA (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>F).<fig id="Fig2" position="float" orientation="portrait"><label>Fig.&#160;2</label><caption><p>Proteome-wide association studies of Juvenile Idiopathic Arthritis in this study. <bold>A</bold>
<italic toggle="yes">P</italic>-value proteome-wide association studies in ARIC of Juvenile Idiopathic Arthritis in this study. <bold>B</bold> Z proteome-wide association studies in ARIC of Juvenile Idiopathic Arthritis in this study. <bold>C</bold>
<italic toggle="yes">P</italic>-value proteome-wide association studies in weight of Juvenile Idiopathic Arthritis in this study. <bold>D</bold> Z proteome-wide association studies in weight of Juvenile Idiopathic Arthritis in this study. <bold>E</bold> transcriptome-wide and proteome-wide association studies result in Juvenile Idiopathic Arthritis. <bold>F</bold> Coloc result in this study</p></caption><graphic id="MO2" position="float" orientation="portrait" xlink:href="12969_2025_1140_Fig2_HTML.jpg"/></fig></p><p id="Par73">Given the potential of proteins with genetic associations to diseases to better elucidate the underlying mechanisms of those diseases, we conducted a TWAS as a crucial part of this research. And, TWAS for JIA were conducted using datas for whole blood from the GTEx v8, YES, and NET projects. TWAS identified 66, 19, and 33 transcript associations in GTEx v8 (8.22&#8201;&#215;&#8201;10<sup>&#8722;6</sup>), YES blood (1.06&#8201;&#215;&#8201;10<sup>&#8722;5</sup>), and NET blood (2.04&#8201;&#215;&#8201;10<sup>&#8722;5</sup>), respectively (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>, Table S6-8). Subsequent colocalization analyses for each identified transcript in the TWAS results and Bayesian co-localization strongly suggested a shared variant between certain transcripts in GTEx v8, YES, and NET with JIA (Table S6-8). Finally, combining TWAS, PWAS and Bayesian co-localization results, we identified ERAP2 as a potential target in the development of JIA (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>E, F). And, Cross-tissue transcriptome-wide association analysis also reported that ERAP2 were closely related to multiple organizations (P<sub>FDR</sub>&#8201;&lt;&#8201;0.05) (Table S9).<fig id="Fig3" position="float" orientation="portrait"><label>Fig.&#160;3</label><caption><p>Transcriptome-wid association studies of Juvenile Idiopathic Arthritis in this study. <bold>A</bold>
<italic toggle="yes">P</italic>-value transcriptome-wide association studies in GTEx V8 blood of Juvenile Idiopathic Arthritis in this study. <bold>B</bold> Z transcriptome-wide association studies in GTEx V8 blood of Juvenile Idiopathic Arthritis in this study. <bold>C</bold>
<italic toggle="yes">P</italic>-value transcriptome-wide association studies in YES blood of Juvenile Idiopathic Arthritis in this study. <bold>D</bold> Z transcriptome-wide association studies in YES blood of Juvenile Idiopathic Arthritis in this study. <bold>E</bold>
<italic toggle="yes">P</italic>- value transcriptome-wide association studies in NET blood of Juvenile Idiopathic Arthritis in this study. <bold>F</bold> Z transcriptome-wide association studies in NET blood of Juvenile Idiopathic Arthritis in this study</p></caption><graphic id="MO3" position="float" orientation="portrait" xlink:href="12969_2025_1140_Fig3_HTML.jpg"/></fig></p><p id="Par74">To determine whether SNPs affect JIA through the modulation of gene and protein expression, we employed 4 step SMR. In the first, two, three step, we conducted eQTL, pQTL and meta-analysis. The pQTL, eQTL and meta-analysis, results and subsequent HEIDI tests further substantiated that the SNP&#8217;s influence on ERAP2 could be due to causal relationships rather than pleiotropy (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>, Table S10-13).<fig id="Fig4" position="float" orientation="portrait"><label>Fig.&#160;4</label><caption><p>Candidate biomarkers identified in this study. <bold>A</bold> Intersection VNN image of eQTL and pQTL in SMR. <bold>B</bold> eQTL, pQTL and meta-analysis result of Juvenile Idiopathic Arthritis in this study</p></caption><graphic id="MO4" position="float" orientation="portrait" xlink:href="12969_2025_1140_Fig4_HTML.jpg"/></fig></p><p id="Par75">In the fourth step, we further assessed the interplay between eQTL and pQTL effects. We discovered that the SNP rs2927608 and rs2910686 can modulate the expression of the ERAP2 gene, thereby regulating the protein content of both ERAP2 and ERAP1 (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>). Additional validation was conducted by querying rs2927608 and rs2910686 in Open Targets Platform, which confirmed its role as a leader SNP influencing both ERAP2 and ERAP1 (Table S14).<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table&#160;1</label><caption><p>Step 4 Summary-data-based Mendelian randomization</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">Expo_Gene</th><th align="left" colspan="1" rowspan="1">Outco_Protein</th><th align="left" colspan="1" rowspan="1">topSNP</th><th align="left" colspan="1" rowspan="1">b_Outco</th><th align="left" colspan="1" rowspan="1">se_Outco</th><th align="left" colspan="1" rowspan="1">p_Outco</th><th align="left" colspan="1" rowspan="1">b_Expo</th><th align="left" colspan="1" rowspan="1">se_Expo</th><th align="left" colspan="1" rowspan="1">p_Expo</th><th align="left" colspan="1" rowspan="1">b_SMR</th><th align="left" colspan="1" rowspan="1">se_SMR</th><th align="left" colspan="1" rowspan="1">p_SMR</th></tr></thead><tbody><tr><td align="left" rowspan="2" colspan="1">GTEX_DECODE</td><td align="left" colspan="1" rowspan="1">ERAP2</td><td align="left" colspan="1" rowspan="1">ERAP1</td><td align="left" colspan="1" rowspan="1">rs2927608</td><td align="left" colspan="1" rowspan="1">&#8722;0.2869</td><td align="left" colspan="1" rowspan="1">0.007983</td><td align="left" colspan="1" rowspan="1">7.55E-283</td><td align="left" colspan="1" rowspan="1">0.993638</td><td align="left" colspan="1" rowspan="1">0.017056</td><td align="left" colspan="1" rowspan="1">0.00E&#8201;+&#8201;00</td><td align="left" colspan="1" rowspan="1">&#8722;0.288737</td><td align="left" colspan="1" rowspan="1">0.00943987</td><td align="left" colspan="1" rowspan="1">1.82E-205</td></tr><tr><td align="left" colspan="1" rowspan="1">ERAP2</td><td align="left" colspan="1" rowspan="1">ERAP2</td><td align="left" colspan="1" rowspan="1">rs2927608</td><td align="left" colspan="1" rowspan="1">1.0603</td><td align="left" colspan="1" rowspan="1">0.003316</td><td align="left" colspan="1" rowspan="1">0.00E&#8201;+&#8201;00</td><td align="left" colspan="1" rowspan="1">0.993638</td><td align="left" colspan="1" rowspan="1">0.017056</td><td align="left" colspan="1" rowspan="1">0.00E&#8201;+&#8201;00</td><td align="left" colspan="1" rowspan="1">1.06709</td><td align="left" colspan="1" rowspan="1">0.018618</td><td align="left" colspan="1" rowspan="1">0.00E&#8201;+&#8201;00</td></tr><tr><td align="left" rowspan="2" colspan="1">EQTL_DECODE</td><td align="left" colspan="1" rowspan="1">ERAP2</td><td align="left" colspan="1" rowspan="1">ERAP1</td><td align="left" colspan="1" rowspan="1">rs2910686</td><td align="left" colspan="1" rowspan="1">&#8722;0.2869</td><td align="left" colspan="1" rowspan="1">0.007982</td><td align="left" colspan="1" rowspan="1">6.42E-283</td><td align="left" colspan="1" rowspan="1">1.0119</td><td align="left" colspan="1" rowspan="1">0.00618304</td><td align="left" colspan="1" rowspan="1">0.00E&#8201;+&#8201;00</td><td align="left" colspan="1" rowspan="1">&#8722;0.283526</td><td align="left" colspan="1" rowspan="1">0.00807615</td><td align="left" colspan="1" rowspan="1">5.34E-270</td></tr><tr><td align="left" colspan="1" rowspan="1">ERAP2</td><td align="left" colspan="1" rowspan="1">ERAP2</td><td align="left" colspan="1" rowspan="1">rs2910686</td><td align="left" colspan="1" rowspan="1">1.0603</td><td align="left" colspan="1" rowspan="1">0.003316</td><td align="left" colspan="1" rowspan="1">0.00E&#8201;+&#8201;00</td><td align="left" colspan="1" rowspan="1">1.0119</td><td align="left" colspan="1" rowspan="1">0.00618304</td><td align="left" colspan="1" rowspan="1">0.00E&#8201;+&#8201;00</td><td align="left" colspan="1" rowspan="1">1.04783</td><td align="left" colspan="1" rowspan="1">0.00719251</td><td align="left" colspan="1" rowspan="1">0.00E&#8201;+&#8201;00</td></tr><tr><td align="left" rowspan="2" colspan="1">GTEX_ARIC</td><td align="left" colspan="1" rowspan="1">ERAP2</td><td align="left" colspan="1" rowspan="1">ERAP1</td><td align="left" colspan="1" rowspan="1">rs2927608</td><td align="left" colspan="1" rowspan="1">&#8722;0.279943</td><td align="left" colspan="1" rowspan="1">0.0165579</td><td align="left" colspan="1" rowspan="1">4.00E-64</td><td align="left" colspan="1" rowspan="1">0.993638</td><td align="left" colspan="1" rowspan="1">0.017056</td><td align="left" colspan="1" rowspan="1">0.00E&#8201;+&#8201;00</td><td align="left" colspan="1" rowspan="1">&#8722;0.281735</td><td align="left" colspan="1" rowspan="1">0.0173515</td><td align="left" colspan="1" rowspan="1">2.76E-59</td></tr><tr><td align="left" colspan="1" rowspan="1">ERAP2</td><td align="left" colspan="1" rowspan="1">ERAP2</td><td align="left" colspan="1" rowspan="1">rs2927608</td><td align="left" colspan="1" rowspan="1">0.98144</td><td align="left" colspan="1" rowspan="1">0.0120847</td><td align="left" colspan="1" rowspan="1">0.00E&#8201;+&#8201;00</td><td align="left" colspan="1" rowspan="1">0.993638</td><td align="left" colspan="1" rowspan="1">0.017056</td><td align="left" colspan="1" rowspan="1">0.00E&#8201;+&#8201;00</td><td align="left" colspan="1" rowspan="1">0.987724</td><td align="left" colspan="1" rowspan="1">0.0208655</td><td align="left" colspan="1" rowspan="1">0.00E&#8201;+&#8201;00</td></tr><tr><td align="left" rowspan="2" colspan="1">GENTLARIC</td><td align="left" colspan="1" rowspan="1">ERAP2</td><td align="left" colspan="1" rowspan="1">ERAP1</td><td align="left" colspan="1" rowspan="1">rs2910686</td><td align="left" colspan="1" rowspan="1">&#8722;0.28055</td><td align="left" colspan="1" rowspan="1">0.0165606</td><td align="left" colspan="1" rowspan="1">2.25E-64</td><td align="left" colspan="1" rowspan="1">1.0119</td><td align="left" colspan="1" rowspan="1">0.00618304</td><td align="left" colspan="1" rowspan="1">0.00E&#8201;+&#8201;00</td><td align="left" colspan="1" rowspan="1">&#8722;0.277251</td><td align="left" colspan="1" rowspan="1">0.0164533</td><td align="left" colspan="1" rowspan="1">1.03E-63</td></tr><tr><td align="left" colspan="1" rowspan="1">ERAP2</td><td align="left" colspan="1" rowspan="1">ERAP2</td><td align="left" colspan="1" rowspan="1">rs2910686</td><td align="left" colspan="1" rowspan="1">0.98165</td><td align="left" colspan="1" rowspan="1">0.0120869</td><td align="left" colspan="1" rowspan="1">0.00E&#8201;+&#8201;00</td><td align="left" colspan="1" rowspan="1">1.0119</td><td align="left" colspan="1" rowspan="1">0.00618304</td><td align="left" colspan="1" rowspan="1">0.00E&#8201;+&#8201;00</td><td align="left" colspan="1" rowspan="1">0.970107</td><td align="left" colspan="1" rowspan="1">0.0133347</td><td align="left" colspan="1" rowspan="1">0.00E&#8201;+&#8201;00</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec21"><title>An independent cohort from the Children&#8217;s Hospital of Chongqing Medical University complemented the above result</title><p id="Par76">In this study, WGS was conducted on the ERAP2 gene in 56 JIA patients, identifying 22,086 variants. And, WGS revealed a homozygous nonsense variation 1176&#160;T&#8201;&gt;&#8201;G in exon7 (rs2549782), Altered splicing variation 1572&#8201;+&#8201;3G&#8201;&gt;&#8201;A in exon 9 (rs2248374) and of ERAP2 gene (Table S15). Additionally, synonymous mutations rs2927608 and rs2910686 in the Chongqing cohort also be found (Table S15). LD analysis showed that R2 values among rs2248374, rs2549782, rs2927608 and rs2910686 were all above 0.8, suggesting these mutations might mediate JIA development through their interactions (Fig. S3). And it was found that it is mainly enriched in sJIA (Table S16).</p><p id="Par77">In Phe-WAS conducted through the Catalog GWAS, FINN Biobanks, and UKB Biobanks, we discovered that rs2927608 and rs2910686 are associated with the occurrence of autoimmune diseases, particularly with Crohn&#8217;s Disease, Inflammatory Bowel Disease, and abnormalities in immune cell function (Figs. S4-6). Additionally, other SNPs related to s2927608 and rs2910686 (R<sup>2</sup>&#8201;&gt;&#8201;0.3) also exhibit strong associations with these autoimmune diseases (Tables S17 and S18). These findings deepen our understanding of the potential roles these SNPs may play in autoimmune diseases and could provide significant molecular targets for future targeted therapies.</p><p id="Par78">Droplet-based scRNA-seq of PMBCs from 14 JIA patients and 4 control was performed on the 10X Genomics platform. Employing a single-cell analysis pipeline, we obtained 177 310 cells among all samples. After removal of poor-quality cells, an unbatched integrated dataset was obtained.</p><p id="Par79">After reducing dimensionality, the cells were clustered and marker genes characteristic of 9 principal cell types/subtypes were assigned. These cell types encompassed CD4&#8201;+&#8201;(CD3D&#8201;+&#8201;CD4&#8201;+), CD8&#8201;+&#8201;(CD3D&#8201;+&#8201;CD8A&#8201;+&#8201;CD8B&#8201;+), and natural killer (NK) (CD3D&#8201;+&#8201;NKG7&#8201;+&#8201;PRF1&#8201;+) T cells, as well as B (CD79A&#8201;+&#8201;CD79B&#8201;+&#8201;MS4A1&#8201;+), plasma (IGHG1&#8201;+&#8201;IGHA1&#8201;+&#8201;JCHAIN&#8201;+), NK cytotoxicity (NKG7&#8201;+&#8201;PRF1&#8201;+), NK inflammation (NKG7&#8201;+&#8201;PRF1&#8201;+&#8201;XCL1&#8201;+) cells, and monocytes (FCN1&#8201;+&#8201;LILRB2&#8201;+&#8201;LILRA5&#8201;+), plasmacytoid dendritic cells (pDCs; LILRA4&#8201;+), and platelets (PPBP&#8201;+) (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>A, B).<fig id="Fig5" position="float" orientation="portrait"><label>Fig.&#160;5</label><caption><p>High-resolution immune cell-type landscape of Juvenile Idiopathic Arthritis and normal. <bold>A</bold> The image showing the expression of cell type-specific marker genes in different immune cells. <bold>B</bold> t-SNE plot showing the identified cell types of all immune cells. <bold>C</bold> ERAP2 differential analysis in Juvenile Idiopathic Arthritis and normal. <bold>D</bold> ERAP2 differential analysis in differential cells. <bold>E</bold> ERAP2 differential analysis in monocytes in Juvenile Idiopathic Arthritis and normal. <bold>F</bold> Pathway changes under high expression levels of ERAP2 in monocytes used irGSEA</p></caption><graphic id="MO5" position="float" orientation="portrait" xlink:href="12969_2025_1140_Fig5_HTML.jpg"/></fig></p><p id="Par80">Subsequently, DEG analysis of the ERAP2 gene revealed a significant upregulation in patients with JIA compared with normal, particularly within the monocyte (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>C-E). Using the irGSEA, it was found that the Inflammation related pathways such as Nod like receptor signaling (NLRs) pathway enrichment score in the ERAP2 high expression group was significantly greater than that in the low expression group in monocytes (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>F). To evaluate the subtype-specific expression pattern of ERAP2 across JIA, we compared its transcript levels in peripheral blood from patients classified by ILAR criteria, as well as from healthy controls. Violin plot analysis revealed that ERAP2 expression was significantly elevated in patients with sJIA compared to all other subtypes, as well as healthy individuals (Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>A). No significant differences were observed between the control group and RF-positive pJIA. These findings indicate that ERAP2 upregulation is highly specific to the sJIA subtype, rather than being a general feature of JIA.<fig id="Fig6" position="float" orientation="portrait"><label>Fig.&#160;6</label><caption><p>Expression and predictive ability validation of ERAP2 in JIA. <bold>A</bold> Expression of ERAP2 in different JIA subtypes in monocyte. <bold>B</bold> ERAP2&#8217;s ability to predict the risk of sJIA</p></caption><graphic id="MO6" position="float" orientation="portrait" xlink:href="12969_2025_1140_Fig6_HTML.jpg"/></fig></p><p id="Par81">In the bulk RNA-sequencing dataset, to further validate these findings, we incorporated an independent cohort comprising 18 additional sJIA samples. ROC curve analysis demonstrated that ERAP2 expression exhibited moderate predictive power in distinguishing sJIA from healthy controls (Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>B).</p><p id="Par82">These findings highlight the potential critical roles of ERAP2 in monocytes in the pathogenesis of JIA and suggest their viability as potential biomarkers for the diagnosis and disease activity monitoring of JIA.</p></sec><sec id="Sec22"><title>Literature review using PubMed and web of science</title><p id="Par83">Our comprehensive literature review, conducted using the PubMed and Web of Science databases, identified 261 publications relevant to ERAP2, detailed in Tables S19-23. The majority of these studies focus on the role of aminopeptidases in therapeutic and pharmacological contexts, with a significant emphasis on diseases related to immunological dysfunctions. Additionally, several studies have proposed the potential of ERAP2 as a diagnostic marker for diseases like neoplasm staging. Notably, inhibitors targeting ERAP2 have entered Phase II clinical trials for cancer treatment. These findings collectively suggest that ERAP2 may serve as a promising therapeutic target in immune-related diseases such as JIA.</p></sec><sec id="Sec23"><title>Druggability of identified targets</title><p id="Par84">Druggability of Identified Targets: we annotated the regions using the Open Targets database. Currently, ERAP2 is associated with approved drugs as detailed in Table&#160;<xref rid="Tab2" ref-type="table">2</xref>. These drugs are utilized across a range of disease categories, including acute myeloid leukemia, myelodysplastic syndrome, non-small cell lung carcinoma, pancreatic carcinoma, and various neoplasms.<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table&#160;2</label><caption><p>ERAP2 clinical trial drug query</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">drugId</th><th align="left" colspan="1" rowspan="1">drugName</th><th align="left" colspan="1" rowspan="1">type</th><th align="left" colspan="1" rowspan="1">mechanismOfAction</th><th align="left" colspan="1" rowspan="1">actionType</th><th align="left" colspan="1" rowspan="1">diseaseId</th><th align="left" colspan="1" rowspan="1">diseaseName</th><th align="left" colspan="1" rowspan="1">phase</th><th align="left" colspan="1" rowspan="1">source</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">CHEMBL2103847</td><td align="left" colspan="1" rowspan="1">TOSEDOSTAT</td><td align="left" colspan="1" rowspan="1">Small molecule</td><td align="left" colspan="1" rowspan="1">Aminopeptidase inhibitor</td><td align="left" colspan="1" rowspan="1">Inhibitor</td><td align="left" colspan="1" rowspan="1">EFO_0000222</td><td align="left" colspan="1" rowspan="1">acute myeloid leukemia</td><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1"><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/study/NCT01180426">https://clinicaltrials.gov/study/NCT01180426</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">CHEMBL2103847</td><td align="left" colspan="1" rowspan="1">TOSEDOSTAT</td><td align="left" colspan="1" rowspan="1">Small molecule</td><td align="left" colspan="1" rowspan="1">Aminopeptidase inhibitor</td><td align="left" colspan="1" rowspan="1">Inhibitor</td><td align="left" colspan="1" rowspan="1">EFO_0000198</td><td align="left" colspan="1" rowspan="1">myelodysplastic syndrome</td><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1"><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/study/NCT02452346">https://clinicaltrials.gov/study/NCT02452346</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">CHEMBL2103847</td><td align="left" colspan="1" rowspan="1">TOSEDOSTAT</td><td align="left" colspan="1" rowspan="1">Small molecule</td><td align="left" colspan="1" rowspan="1">Aminopeptidase inhibitor</td><td align="left" colspan="1" rowspan="1">Inhibitor</td><td align="left" colspan="1" rowspan="1">EFO_0000222</td><td align="left" colspan="1" rowspan="1">acute myeloid leukemia</td><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1"><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/study/NCT00780598">https://clinicaltrials.gov/study/NCT00780598</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">CHEMBL2103847</td><td align="left" colspan="1" rowspan="1">TOSEDOSTAT</td><td align="left" colspan="1" rowspan="1">Small molecule</td><td align="left" colspan="1" rowspan="1">Aminopeptidase inhibitor</td><td align="left" colspan="1" rowspan="1">Inhibitor</td><td align="left" colspan="1" rowspan="1">EFO_0003060</td><td align="left" colspan="1" rowspan="1">non-small cell lung carcinoma</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1"><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/study/NCT00522938">https://clinicaltrials.gov/study/NCT00522938</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">CHEMBL2103847</td><td align="left" colspan="1" rowspan="1">TOSEDOSTAT</td><td align="left" colspan="1" rowspan="1">Small molecule</td><td align="left" colspan="1" rowspan="1">Aminopeptidase inhibitor</td><td align="left" colspan="1" rowspan="1">Inhibitor</td><td align="left" colspan="1" rowspan="1">EFO_0002618</td><td align="left" colspan="1" rowspan="1">pancreatic carcinoma</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1"><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/study/NCT02352831">https://clinicaltrials.gov/study/NCT02352831</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">CHEMBL2103847</td><td align="left" colspan="1" rowspan="1">TOSEDOSTAT</td><td align="left" colspan="1" rowspan="1">Small molecule</td><td align="left" colspan="1" rowspan="1">Aminopeptidase inhibitor</td><td align="left" colspan="1" rowspan="1">Inhibitor</td><td align="left" colspan="1" rowspan="1">EFO_0000616</td><td align="left" colspan="1" rowspan="1">neoplasm</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1"><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/study/NCT00692354">https://clinicaltrials.gov/study/NCT00692354</ext-link></td></tr></tbody></table></table-wrap></p></sec></sec><sec id="Sec24"><title>Discussion</title><p id="Par85">Using an Integrative Omics Pipeline, we generated a comprehensive genome-wide catalog of potential causal contributors to JIA. We identified several associations between genetic models of gene expression and proteins with genetic determinants of JIA. In summary, our findings from the Integrative Omics Pipeline indicated a close relationship between ERAP2 and the incidence of JIA. To corroborate this connection and further investigate the regulatory mechanisms and potential drug targets of the identified proteins, subsequent analyses, including WGS and scRNA-seq, were performed. These studies helped validate our findings and provided deeper insights into the biological underpinnings of JIA.</p><p id="Par86">ERAP2 is an aminopeptidase located on chromosome 5q15, adjacent to ERAP1 and LNPEP, forming a functional subfamily of mammalian zinc aminopeptidases (or M1 metallopeptidases) [<xref ref-type="bibr" rid="CR26">26</xref>]. These enzymes cleave the N-terminal amino acids of bioactive and antigenic peptides. Within the endoplasmic reticulum, ERAP2 processes N-terminally extended precursor peptides, crucial for their binding to MHC-I and presentation on the cell surface to T cells, thereby playing a key role in antigen processing to initiate immune responses against infected cells [<xref ref-type="bibr" rid="CR27">27</xref>]. In this study, by using the Integrative Omics Pipeline, we found a close relationship between ERAP2 and JIA risk.</p><p id="Par87">The credibility of our methodology is reinforced by the orthogonal support provided by literature reviews. Numerous studies have shown that single nucleotide variants in the ERAP2 gene are linked with a higher risk of various chronic inflammatory diseases, including Crohn&#8217;s disease, and ankylosing spondylitis [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. In addition, these genetic variations are also associated with infections such as pneumonia and bubonic plague [<xref ref-type="bibr" rid="CR30">30</xref>&#8211;<xref ref-type="bibr" rid="CR33">33</xref>]. Moreover, growing evidence suggests ERAP2 as a promising therapeutic target for autoimmune conditions. Researchers like Evnouchidou et al. argue that understanding the precise role and mechanism of these aminopeptidases could facilitate the development of nuanced and precise pharmaceutical interventions to modulate immune responses [<xref ref-type="bibr" rid="CR34">34</xref>]. This understanding has the potential to unlock new therapeutic strategies for a spectrum of diseases, ranging from autoimmune disorders to cancer.</p><p id="Par88">In terms of function, ERAP2 encodes an endoplasmic reticulum aminopeptidase involved in the trimming of peptide precursors for optimal MHC class I presentation. It is well established that ERAP2 expression is transcriptionally upregulated by proinflammatory cytokines, particularly IFN-&#947;and tumor necrosis factor-alpha TNF-&#945;), both of which are markedly elevated in sJIA and MAS&#8212;a life-threatening complication of sJIA [<xref ref-type="bibr" rid="CR35">35</xref>]. This cytokine-driven regulation positions ERAP2 as a dynamic responder to inflammatory stimuli within the immune microenvironment. Beyond its canonical role in antigen processing, emerging evidence suggests that ERAP2 also contributes to the shaping of the extracellular cytokine milieu. Notably, the secreted form of ERAP2 has been shown to cleave and modulate the activity of extracellular substrates, including IL-1&#946; and IL-18 precursors, both of which are key drivers of systemic inflammation and innate immune activation in sJIA. Through this mechanism, ERAP2 may influence the magnitude and duration of the IL-1/IL-18 axis, thereby contributing to excessive activation of macrophages and downstream cytokine cascades. The specific association between ERAP2 and JIA, however, requires further investigation. We speculate that ERAP2-mediated JIA may be closely related to excessive immune activation. ERAP2 plays a critical role in trimming peptides to optimal lengths for MHC class I presentation, a process essential for proper immune cell function. Deviations in this trimming process may lead to aberrant antigen presentation and abnormal immune responses [<xref ref-type="bibr" rid="CR27">27</xref>]. In the context of JIA, polymorphisms in the ERAP2 gene have been associated with increased disease susceptibility, potentially by promoting the presentation of self-antigens in genetically predisposed individuals. In support of this, our SMR analysis identified two SNPs, rs2927608 and rs2910686, which regulate ERAP2 expression and are associated with elevated ERAP2 protein levels. This increase may exacerbate immune responses and contribute to immune dysregulation. Moreover, single-cell RNA-seq data revealed a significant increase in ERAP2 expression in monocytes&#8212;key antigen-presenting cells responsible for initiating T-cell responses [<xref ref-type="bibr" rid="CR36">36</xref>]. Since ERAP2 facilitates MHC-I&#8211;restricted antigen presentation, its overexpression in monocytes could skew antigen processing, increasing the likelihood of autoantigen presentation and promoting autoimmune activation. Given the complexity and heterogeneity of JIA, these findings underscore the importance of ERAP2 as a potential contributor to disease pathogenesis, and highlight the need for further mechanistic studies. A deeper understanding of ERAP2&#8217;s immunological roles may not only clarify the pathways underlying JIA onset but also offer new avenues for therapeutic targeting and biomarker development, particularly for subtype-specific interventions.</p><p id="Par89">Although classical GWAS initially identified ERAP1 rather than ERAP2 as a risk locus in ERA and other HLA-B27&#8211;associated spondyloarthritides, more recent 3D genome and eQTL meta-analyses have shown that JIA-associated SNPs converge on the transcriptional upregulation of ERAP2 across immune tissues, suggesting a broader role in systemic inflammation [<xref ref-type="bibr" rid="CR37">37</xref>]. Our transcriptomic data further extend these findings by demonstrating that ERAP2 is most actively transcribed in sJIA, indicating that its function may be subtype-specific. Mechanistically, ERAP2 is a canonical interferon-stimulated gene that is strongly induced by IFN-&#947; and TNF-&#945;&#8212;cytokines highly elevated in sJIA and MAS. Beyond its classical role in trimming peptides for MHC class I presentation, ERAP2 may influence disease processes through multiple pathways: (1) secreted ERAP2 may cleave IL-1&#946; and IL-18 precursors, modulating the intensity of innate immune responses and contributing to cytokine storm&#8211;like states [<xref ref-type="bibr" rid="CR38">38</xref>]; (2) its involvement in degrading angiotensin III/IV links ERAP2 to endothelial dysfunction and episodic hypertension, features sometimes observed in severe sJIA [<xref ref-type="bibr" rid="CR27">27</xref>]; Together, these findings support a model in which ERAP2 contributes to sJIA pathogenesis through antigen presentation dysregulation, inflammatory amplification, vascular modulation, and gene&#8211;environment synergy, highlighting its potential value as a biomarker and therapeutic target.</p><p id="Par90">The specific association between ERAP2 and JIA requires further investigation. We speculate that ERAP2 mediated JIA may be closely related to Excessive immune response. ERAP2's critical role involves trimming peptides to optimal lengths for presentation by MHC class I molecules, a process essential for the correct functioning of immune cells. Any deviation in this process may lead to abnormal immune cell behavior, potentially triggering autoimmune responses [<xref ref-type="bibr" rid="CR27">27</xref>]. In the context of JIA, the association between polymorphisms in ERAP2 and increased susceptibility to the disease is particularly notable. These genetic variations could affect the presentation of autoantigens, leading to excessive immune response in individuals who are genetically predisposed. For example, in the fourth step of SMR analysis, we discovered that the SNP rs2927608 and rs2910686 can regulate the expression of the ERAP2 gene, thereby increasing the protein content of ERAP2. An increase in ERAP2 protein levels may exacerbate immune responses, leading to immune system dysregulation and ultimately contributing to JIA. Besides, in scRNA-seq, we found a significant increase in ERAP2 expression in monocytes. Monocytes are key antigen presenting cells that process and present antigens to T cells, initiating immune responses [<xref ref-type="bibr" rid="CR36">36</xref>]. ERAP2's role in trimming peptides for MHC class I molecule presentation enhances this process. Overexpression in monocytes could therefore lead to alterations in how antigens are presented, potentially increasing the presentation of autoantigens that trigger autoimmune responses. Given the complexity of JIA, understanding the role of ERAP2 provides crucial insights into the disease's pathogenesis. This knowledge could open new pathways for therapeutic interventions, underscoring the importance of further investigating the specific association between ERAP2 and JIA. This type of research is essential not only to confirm ERAP2 as a therapeutic target but also to potentially identify new biomarkers that could inform on disease prognosis and the efficacy of treatments.</p><p id="Par91">In scRNA-seq analysis, using the irGSEA, we discovered that many immune pathways are intimately linked to elevated expression of ERAP2, particularly the NLRs pathway associated with infection. The NLR family, consisting of 22 known protein members in humans, is integral to innate immunity and inflammation. These proteins function as cytosolic pattern recognition receptors that are pivotal for detecting pathogen-associated molecular patterns and triggering immune responses [<xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR40">40</xref>]. Each NLR protein contains a nucleotide-binding oligomerization domain (NOD), vital for self-oligomerization&#8212;a critical process in the innate immune response [<xref ref-type="bibr" rid="CR41">41</xref>]. Research has shown that disruptions in the signaling pathways of these receptors, often due to functional anomalies, can result in cytokine imbalances. Specifically, abnormalities in interleukin-1 (IL-1) and interleukin-6 (IL-6) are associated with increased susceptibility to non-invasive inflammatory diseases such as JIA, rheumatoid arthritis, and systemic lupus erythematosus, among other autoimmune inflammatory conditions [<xref ref-type="bibr" rid="CR42">42</xref>&#8211;<xref ref-type="bibr" rid="CR44">44</xref>]. Importantly, recent studies reported that overexpression of ERAP2 triggers the assembly of the inflammasome and activates Caspase-1, thereby indirectly influencing the activation of NLRs [<xref ref-type="bibr" rid="CR45">45</xref>]. The interaction between ERAP2 and NLRs not only highlights a crucial mechanism but also underscores its significance in promoting JIA. This underscores the potential of targeting these pathways for therapeutic interventions.</p><p id="Par92">This study highlights the comprehensive scope of our screening model, which encompasses 6,083 genes and 1,349 proteins. The independence of TWAS and PWAS from requiring GWAS trait associations within the same dataset allowed us to utilize summary statistics from consortia with larger sample sizes, thereby maximizing our capacity to detect associations. By conducting additional colocalization analyses, we minimized the risks of confounding and reverse causation. Furthermore, the validation in independent cohorts enhances the generalizability of our findings regarding these targets. However, this article also has some limitations. Due to the multiple subtypes of JIA, we need to further explore the precise relationship between ERAP2 and each subtype using larger samples.</p></sec><sec id="Sec25"><title>Conclusions</title><p id="Par93">In conclusion, this study has constructed a catalog of potentially causal target genes, tissues, and proteins implicated in JIA, providing a valuable resource to support future research in physiology, basic science, and clinical medicine. Among the candidates identified, ERAP2 showed consistent multi-omics evidence of involvement in JIA, particularly in sJIA. Our analyses suggest that ERAP2 may contribute to disease pathogenesis through protein-mediated mechanisms and highlight its potential as a therapeutic target.</p></sec><sec id="Sec26" sec-type="supplementary-material"><title>Supplementary Information</title><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xlink:href="12969_2025_1140_MOESM1_ESM.pdf" position="float" orientation="portrait"><caption><p>Supplementary Material 1: Figure S1. Linkage Disequilibrium Score Regressionresult in this study</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2" position="float" orientation="portrait"><media xlink:href="12969_2025_1140_MOESM2_ESM.pdf" position="float" orientation="portrait"><caption><p>Supplementary Material 2: Figure S2. Multi-marker Analysis of GenoMic Annotation result in this study</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM3" position="float" orientation="portrait"><media xlink:href="12969_2025_1140_MOESM3_ESM.pdf" position="float" orientation="portrait"><caption><p>Supplementary Material 3: Figure S3. Linkage disequilibrium analysis that R<sup>2</sup> values among rs2248374, rs2549782, rs2927608 and rs2910686.</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM4" position="float" orientation="portrait"><media xlink:href="12969_2025_1140_MOESM4_ESM.pdf" position="float" orientation="portrait"><caption><p>Supplementary Material 4: Figure S4. Phenome-wide association study in Catalog GWAS</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM5" position="float" orientation="portrait"><media xlink:href="12969_2025_1140_MOESM5_ESM.pdf" position="float" orientation="portrait"><caption><p>Supplementary Material 5: Figure S5. Phenome-wide association study in Finn Biobank</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM6" position="float" orientation="portrait"><media xlink:href="12969_2025_1140_MOESM6_ESM.pdf" position="float" orientation="portrait"><caption><p>Supplementary Material 6: Figure S6. Phenome-wide association study in UKB Biobanks</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM7" position="float" orientation="portrait"><media xlink:href="12969_2025_1140_MOESM7_ESM.xlsx" position="float" orientation="portrait"><caption><p>Supplementary Material 7.</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM8" position="float" orientation="portrait"><media xlink:href="12969_2025_1140_MOESM8_ESM.xlsx" position="float" orientation="portrait"><caption><p>Supplementary Material 8.</p></caption></media></supplementary-material>
</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>GWAS</term><def><p id="Par5">Genome-wide association studies</p></def></def-item><def-item><term>JIA</term><def><p id="Par6">Juvenile Idiopathic Arthritis</p></def></def-item><def-item><term>WGS</term><def><p id="Par7">Whole Genome Sequencing</p></def></def-item><def-item><term>scRNA-seq</term><def><p id="Par8">Single-cell RNA sequencing</p></def></def-item><def-item><term>Bulk RNA-seq</term><def><p id="Par9">Bulk RNA sequencing</p></def></def-item><def-item><term>NSAIDs</term><def><p id="Par10">Non-steroidal anti-inflammatory drugs</p></def></def-item><def-item><term>tsDMARDs</term><def><p id="Par11">Traditional synthetic disease-modifying anti-rheumatic drugs</p></def></def-item><def-item><term>DMARDs</term><def><p id="Par12">Disease-modifying anti-rheumatic drugs</p></def></def-item><def-item><term>TWAS</term><def><p id="Par13">Transcriptome-wide association study</p></def></def-item><def-item><term>PWAS</term><def><p id="Par14">Proteome-wide association studies</p></def></def-item><def-item><term>MR</term><def><p id="Par15">Mendelian randomization</p></def></def-item><def-item><term>ERAP2</term><def><p id="Par16">Endoplasmic reticulum aminopeptidase 2</p></def></def-item><def-item><term>Phe-WAS</term><def><p id="Par17">Phenome-wide association study</p></def></def-item><def-item><term>SNPs</term><def><p id="Par18">Single nucleotide polymorphisms</p></def></def-item><def-item><term>MAF</term><def><p id="Par19">Minor allele frequency</p></def></def-item><def-item><term>LDSC</term><def><p id="Par20">Linkage Disequilibrium Score Regression</p></def></def-item><def-item><term>LD</term><def><p id="Par21">Linkage Disequilibrium</p></def></def-item><def-item><term>S-LDSC</term><def><p id="Par22">Stratified Linkage Disequilibrium Score Regression</p></def></def-item><def-item><term>DGF</term><def><p id="Par23">DNase I digital genomic foot-printing</p></def></def-item><def-item><term>DHSs</term><def><p id="Par24">DNase I hypersensitive sites</p></def></def-item><def-item><term>MAGMA</term><def><p id="Par25">Multi-marker Analysis of GenoMic Annotation</p></def></def-item><def-item><term>ARIC</term><def><p id="Par26">Atherosclerosis Risk in Communities</p></def></def-item><def-item><term>NTR</term><def><p id="Par27">Netherlands Twin Register</p></def></def-item><def-item><term>YFS</term><def><p id="Par28">Young Finns Study</p></def></def-item><def-item><term>eQTL</term><def><p id="Par29">Expression Quantitative Trait Loci</p></def></def-item><def-item><term>PPH4</term><def><p id="Par30">Posterior probability for hypothesis H4</p></def></def-item><def-item><term>SMR</term><def><p id="Par31">Summary-data-based Mendelian Randomization</p></def></def-item><def-item><term>pQTL</term><def><p id="Par32">Protein Quantitative Trait Loci</p></def></def-item><def-item><term>HEIDI</term><def><p id="Par33">Heterogeneity In Dependent Instruments</p></def></def-item><def-item><term>VCF</term><def><p id="Par34">Variant Call Format</p></def></def-item><def-item><term>ILAR</term><def><p id="Par35">League of Associations for Rheumatology</p></def></def-item><def-item><term>BWA</term><def><p id="Par36">Burrows-Wheeler Aligner</p></def></def-item><def-item><term>InDels</term><def><p id="Par37">Insertions or deletions</p></def></def-item><def-item><term>DEGs</term><def><p id="Par38">Differentially expressed genes</p></def></def-item><def-item><term>NLRs</term><def><p id="Par39">Nod like receptor signaling</p></def></def-item><def-item><term>NOD</term><def><p id="Par40">Nucleotide-binding oligomerization domain</p></def></def-item><def-item><term>IL-1</term><def><p id="Par41">Interleukin-1</p></def></def-item><def-item><term>IL-6</term><def><p id="Par42">Interleukin-6</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#8217;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We sincerely thank all patients in this study and their families for their participation and support.</p></ack><notes notes-type="author-contribution"><title>Authors&#8217; contributions</title><p>XMT contributed equally in the design and coordination of the study; XMT conceived the study, participated in its design and helped to draft the final version of the manuscript; XLW and QL carried out the sequencing techniques and helped to draft the manuscript and data interpretation; XWL, FML, DWL and CXM helped to perform the sequencing techniques; All the authors approved the final version of the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This work was supported by grants from the National Key R&amp;D Program of China (No. 2021YFC2702003).</p></notes><notes notes-type="data-availability"><title>Data Availability</title><p>Data are available on reasonable request. All data can be obtained by contacting the corresponding author.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par94">The studies were reviewed and approved by the ethics committee of Children&#8217;s Hospital Affiliated with Chongqing Medical University.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par95">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par96">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petty</surname><given-names>RE</given-names></name><name name-style="western"><surname>Southwood</surname><given-names>TR</given-names></name><name name-style="western"><surname>Manners</surname><given-names>P</given-names></name><etal/></person-group><article-title>International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001</article-title><source>J Rheumatol</source><year>2004</year><volume>31</volume><issue>2</issue><fpage>390</fpage><lpage>392</lpage><pub-id pub-id-type="pmid">14760812</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390&#8211;2.<pub-id pub-id-type="pmid">14760812</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cimaz</surname><given-names>R</given-names></name></person-group><article-title>Systemic-onset juvenile idiopathic arthritis</article-title><source>Autoimmun Rev</source><year>2016</year><volume>15</volume><issue>9</issue><fpage>931</fpage><lpage>934</lpage><pub-id pub-id-type="pmid">27392503</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.autrev.2016.07.004</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Cimaz R. Systemic-onset juvenile idiopathic arthritis. Autoimmun Rev. 2016;15(9):931&#8211;4.<pub-id pub-id-type="pmid">27392503</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.autrev.2016.07.004</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martini</surname><given-names>A</given-names></name><name name-style="western"><surname>Lovell</surname><given-names>DJ</given-names></name></person-group><article-title>Juvenile idiopathic arthritis: state of the art and future perspectives</article-title><source>Ann Rheum Dis</source><year>2010</year><volume>69</volume><issue>7</issue><fpage>1260</fpage><lpage>1263</lpage><pub-id pub-id-type="pmid">20525835</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/ard.2010.133033</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Martini A, Lovell DJ. Juvenile idiopathic arthritis: state of the art and future perspectives. Ann Rheum Dis. 2010;69(7):1260&#8211;3.<pub-id pub-id-type="pmid">20525835</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/ard.2010.133033</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thierry</surname><given-names>S</given-names></name><name name-style="western"><surname>Fautrel</surname><given-names>B</given-names></name><name name-style="western"><surname>Lemelle</surname><given-names>I</given-names></name><name name-style="western"><surname>Guillemin</surname><given-names>F</given-names></name></person-group><article-title>Prevalence and incidence of juvenile idiopathic arthritis: a systematic review</article-title><source>Joint Bone Spine</source><year>2014</year><volume>81</volume><issue>2</issue><fpage>112</fpage><lpage>117</lpage><pub-id pub-id-type="pmid">24210707</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jbspin.2013.09.003</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Thierry S, Fautrel B, Lemelle I, Guillemin F. Prevalence and incidence of juvenile idiopathic arthritis: a systematic review. Joint Bone Spine. 2014;81(2):112&#8211;7.<pub-id pub-id-type="pmid">24210707</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jbspin.2013.09.003</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kimura</surname><given-names>Y</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>JE</given-names></name><name name-style="western"><surname>Haroldson</surname><given-names>KL</given-names></name><etal/></person-group><article-title>Pulmonary hypertension and other potentially fatal pulmonary complications in systemic juvenile idiopathic arthritis</article-title><source>Arthritis Care Res (Hoboken)</source><year>2013</year><volume>65</volume><issue>5</issue><fpage>745</fpage><lpage>752</lpage><pub-id pub-id-type="pmid">23139240</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/acr.21889</pub-id><pub-id pub-id-type="pmcid">PMC4476507</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Kimura Y, Weiss JE, Haroldson KL, et al. Pulmonary hypertension and other potentially fatal pulmonary complications in systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2013;65(5):745&#8211;52.<pub-id pub-id-type="pmid">23139240</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/acr.21889</pub-id><pub-id pub-id-type="pmcid">PMC4476507</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nigrovic</surname><given-names>PA</given-names></name></person-group><article-title>Review: is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis?</article-title><source>Arthritis Rheumatol</source><year>2014</year><volume>66</volume><issue>6</issue><fpage>1405</fpage><lpage>1413</lpage><pub-id pub-id-type="pmid">24623686</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/art.38615</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Nigrovic PA. Review: is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis? Arthritis Rheumatol. 2014;66(6):1405&#8211;13.<pub-id pub-id-type="pmid">24623686</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/art.38615</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Minden</surname><given-names>K</given-names></name><name name-style="western"><surname>Niewerth</surname><given-names>M</given-names></name><name name-style="western"><surname>Listing</surname><given-names>J</given-names></name><etal/></person-group><article-title>The economic burden of juvenile idiopathic arthritis-results from the German paediatric rheumatologic database</article-title><source>Clin Exp Rheumatol</source><year>2009</year><volume>27</volume><issue>5</issue><fpage>863</fpage><lpage>869</lpage><pub-id pub-id-type="pmid">19917175</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Minden K, Niewerth M, Listing J, et al. The economic burden of juvenile idiopathic arthritis-results from the German paediatric rheumatologic database. Clin Exp Rheumatol. 2009;27(5):863&#8211;9.<pub-id pub-id-type="pmid">19917175</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Giancane</surname><given-names>G</given-names></name><name name-style="western"><surname>Consolaro</surname><given-names>A</given-names></name><name name-style="western"><surname>Lanni</surname><given-names>S</given-names></name><name name-style="western"><surname>Dav&#236;</surname><given-names>S</given-names></name><name name-style="western"><surname>Schiappapietra</surname><given-names>B</given-names></name><name name-style="western"><surname>Ravelli</surname><given-names>A</given-names></name></person-group><article-title>Juvenile idiopathic arthritis: diagnosis and treatment</article-title><source>Rheumatol Ther</source><year>2016</year><volume>3</volume><issue>2</issue><fpage>187</fpage><lpage>207</lpage><pub-id pub-id-type="pmid">27747582</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40744-016-0040-4</pub-id><pub-id pub-id-type="pmcid">PMC5127964</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Giancane G, Consolaro A, Lanni S, Dav&#236; S, Schiappapietra B, Ravelli A. Juvenile idiopathic arthritis: diagnosis and treatment. Rheumatol Ther. 2016;3(2):187&#8211;207.<pub-id pub-id-type="pmid">27747582</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40744-016-0040-4</pub-id><pub-id pub-id-type="pmcid">PMC5127964</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schett</surname><given-names>G</given-names></name><name name-style="western"><surname>McInnes</surname><given-names>IB</given-names></name><name name-style="western"><surname>Neurath</surname><given-names>MF</given-names></name></person-group><article-title>Reframing immune-mediated inflammatory diseases through signature cytokine hubs</article-title><source>N Engl J Med</source><year>2021</year><volume>385</volume><issue>7</issue><fpage>628</fpage><lpage>639</lpage><pub-id pub-id-type="pmid">34379924</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMra1909094</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Schett G, McInnes IB, Neurath MF. Reframing immune-mediated inflammatory diseases through signature cytokine hubs. N Engl J Med. 2021;385(7):628&#8211;39.<pub-id pub-id-type="pmid">34379924</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMra1909094</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Giancane</surname><given-names>G</given-names></name><name name-style="western"><surname>Muratore</surname><given-names>V</given-names></name><name name-style="western"><surname>Marzetti</surname><given-names>V</given-names></name><name name-style="western"><surname>Quilis</surname><given-names>N</given-names></name><name name-style="western"><surname>Benavente</surname><given-names>BS</given-names></name><name name-style="western"><surname>Bagnasco</surname><given-names>F</given-names></name><etal/></person-group><article-title>Disease activity and damage in juvenile idiopathic arthritis: methotrexate era versus biologic era</article-title><source>Arthritis Res Ther</source><year>2019</year><volume>21</volume><issue>1</issue><fpage>168</fpage><pub-id pub-id-type="pmid">31287015</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13075-019-1950-7</pub-id><pub-id pub-id-type="pmcid">PMC6615271</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Giancane G, Muratore V, Marzetti V, Quilis N, Benavente BS, Bagnasco F, et al. Disease activity and damage in juvenile idiopathic arthritis: methotrexate era versus biologic era. Arthritis Res Ther. 2019;21(1):168.<pub-id pub-id-type="pmid">31287015</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13075-019-1950-7</pub-id><pub-id pub-id-type="pmcid">PMC6615271</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mat&#237;as-Garc&#237;a</surname><given-names>PR</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>R</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Plasma proteomics of renal function: a transethnic meta-analysis and Mendelian randomization study</article-title><source>J Am Soc Nephrol</source><year>2021</year><volume>32</volume><issue>7</issue><fpage>1747</fpage><lpage>1763</lpage><pub-id pub-id-type="pmid">34135082</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1681/ASN.2020071070</pub-id><pub-id pub-id-type="pmcid">PMC8425654</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Mat&#237;as-Garc&#237;a PR, Wilson R, Guo Q, et al. Plasma proteomics of renal function: a transethnic meta-analysis and Mendelian randomization study. J Am Soc Nephrol. 2021;32(7):1747&#8211;63.<pub-id pub-id-type="pmid">34135082</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1681/ASN.2020071070</pub-id><pub-id pub-id-type="pmcid">PMC8425654</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suhre</surname><given-names>K</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>M</given-names></name><name name-style="western"><surname>Bhagwat</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Connecting genetic risk to disease end points through the human blood plasma proteome</article-title><source>Nat Commun</source><year>2017</year><volume>8</volume><fpage>14357</fpage><pub-id pub-id-type="pmid">28240269</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ncomms14357</pub-id><pub-id pub-id-type="pmcid">PMC5333359</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Suhre K, Arnold M, Bhagwat AM, et al. Connecting genetic risk to disease end points through the human blood plasma proteome. Nat Commun. 2017;8:14357.<pub-id pub-id-type="pmid">28240269</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ncomms14357</pub-id><pub-id pub-id-type="pmcid">PMC5333359</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gusev</surname><given-names>A</given-names></name><etal/></person-group><article-title>Integrative approaches for large-scale transcriptome-wide association studies</article-title><source>Nat Genet</source><year>2016</year><volume>48</volume><fpage>245</fpage><lpage>252</lpage><pub-id pub-id-type="pmid">26854917</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ng.3506</pub-id><pub-id pub-id-type="pmcid">PMC4767558</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Gusev A, et al. Integrative approaches for large-scale transcriptome-wide association studies. Nat Genet. 2016;48:245&#8211;52.<pub-id pub-id-type="pmid">26854917</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ng.3506</pub-id><pub-id pub-id-type="pmcid">PMC4767558</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="other">Zhang J, et al. Plasma proteome analyses in individuals of European and African ancestry identify cis-pQTLs and models for proteome-wide association studies. Nat Genet. 2022:2021.03.15.435533.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41588-022-01051-w</pub-id><pub-id pub-id-type="pmcid">PMC9236177</pub-id><pub-id pub-id-type="pmid">35501419</pub-id></mixed-citation></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X</given-names></name></person-group><article-title>Transcriptome-wide association studies: a view from Mendelian randomization</article-title><source>Quant Biol</source><year>2021</year><volume>9</volume><fpage>107</fpage><lpage>121</lpage><pub-id pub-id-type="pmid">35433074</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40484-020-0207-4</pub-id><pub-id pub-id-type="pmcid">PMC9009829</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Zhu H, Zhou X. Transcriptome-wide association studies: a view from Mendelian randomization. Quant Biol. 2021;9:107&#8211;21.<pub-id pub-id-type="pmid">35433074</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40484-020-0207-4</pub-id><pub-id pub-id-type="pmcid">PMC9009829</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>J</given-names></name><etal/></person-group><article-title>Phenome-wide Mendelian randomization mapping the influence of the plasma proteome on complex diseases</article-title><source>Nat Genet</source><year>2020</year><volume>52</volume><fpage>1122</fpage><lpage>1131</lpage><pub-id pub-id-type="pmid">32895551</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41588-020-0682-6</pub-id><pub-id pub-id-type="pmcid">PMC7610464</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Zheng J, et al. Phenome-wide Mendelian randomization mapping the influence of the plasma proteome on complex diseases. Nat Genet. 2020;52:1122&#8211;31.<pub-id pub-id-type="pmid">32895551</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41588-020-0682-6</pub-id><pub-id pub-id-type="pmcid">PMC7610464</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wallace</surname><given-names>C</given-names></name></person-group><article-title>A more accurate method for colocalisation analysis allowing for multiple causal variants</article-title><source>PLoS Genet</source><year>2021</year><volume>17</volume><fpage>e1009440</fpage><pub-id pub-id-type="pmid">34587156</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pgen.1009440</pub-id><pub-id pub-id-type="pmcid">PMC8504726</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Wallace C. A more accurate method for colocalisation analysis allowing for multiple causal variants. PLoS Genet. 2021;17:e1009440.<pub-id pub-id-type="pmid">34587156</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pgen.1009440</pub-id><pub-id pub-id-type="pmcid">PMC8504726</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Giambartolomei</surname><given-names>C</given-names></name><etal/></person-group><article-title>Bayesian test for colocalisation between pairs of genetic association studies using summary statistics</article-title><source>PLoS Genet</source><year>2014</year><volume>10</volume><fpage>e1004383</fpage><pub-id pub-id-type="pmid">24830394</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pgen.1004383</pub-id><pub-id pub-id-type="pmcid">PMC4022491</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Giambartolomei C, et al. Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. PLoS Genet. 2014;10:e1004383.<pub-id pub-id-type="pmid">24830394</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pgen.1004383</pub-id><pub-id pub-id-type="pmcid">PMC4022491</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>L&#243;pez-Isac</surname><given-names>E</given-names></name><name name-style="western"><surname>Smith</surname><given-names>SL</given-names></name><name name-style="western"><surname>Marion</surname><given-names>MC</given-names></name><etal/></person-group><article-title>Combined genetic analysis of juvenile idiopathic arthritis clinical subtypes identifies novel risk loci, target genes and key regulatory mechanisms</article-title><source>Ann Rheum Dis</source><year>2021</year><volume>80</volume><issue>3</issue><fpage>321</fpage><lpage>328</lpage><pub-id pub-id-type="pmid">33106285</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/annrheumdis-2020-218481</pub-id><pub-id pub-id-type="pmcid">PMC7892389</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">L&#243;pez-Isac E, Smith SL, Marion MC, et al. Combined genetic analysis of juvenile idiopathic arthritis clinical subtypes identifies novel risk loci, target genes and key regulatory mechanisms. Ann Rheum Dis. 2021;80(3):321&#8211;8.<pub-id pub-id-type="pmid">33106285</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/annrheumdis-2020-218481</pub-id><pub-id pub-id-type="pmcid">PMC7892389</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Finucane</surname><given-names>HK</given-names></name><name name-style="western"><surname>Bulik-Sullivan</surname><given-names>B</given-names></name><name name-style="western"><surname>Gusev</surname><given-names>A</given-names></name><etal/></person-group><article-title>Partitioning heritability by functional annotation using genome-wide association summary statistics</article-title><source>Nat Genet</source><year>2015</year><volume>47</volume><fpage>1228</fpage><lpage>1235</lpage><pub-id pub-id-type="pmid">26414678</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ng.3404</pub-id><pub-id pub-id-type="pmcid">PMC4626285</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Finucane HK, Bulik-Sullivan B, Gusev A, et al. Partitioning heritability by functional annotation using genome-wide association summary statistics. Nat Genet. 2015;47:1228&#8211;35.<pub-id pub-id-type="pmid">26414678</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ng.3404</pub-id><pub-id pub-id-type="pmcid">PMC4626285</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Leeuw</surname><given-names>CA</given-names></name><name name-style="western"><surname>Mooij</surname><given-names>JM</given-names></name><name name-style="western"><surname>Heskes</surname><given-names>T</given-names></name><name name-style="western"><surname>Posthuma</surname><given-names>D</given-names></name></person-group><article-title>MAGMA: generalized gene-set analysis of GWAS data</article-title><source>PLoS Comput Biol</source><year>2015</year><volume>11</volume><fpage>e1004219</fpage><pub-id pub-id-type="pmid">25885710</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pcbi.1004219</pub-id><pub-id pub-id-type="pmcid">PMC4401657</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">de Leeuw CA, Mooij JM, Heskes T, Posthuma D. MAGMA: generalized gene-set analysis of GWAS data. PLoS Comput Biol. 2015;11:e1004219.<pub-id pub-id-type="pmid">25885710</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pcbi.1004219</pub-id><pub-id pub-id-type="pmcid">PMC4401657</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="other">Zhang J, Dutta D, K&#246;ttgen A, et al. Plasma proteome analyses in individuals of European and African ancestry identify cis-pQTLs and models for proteome-wide association studies. Nat Genet. 2022;54(5):593-602. 10.1038/s41588-022-01051-w.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41588-022-01051-w</pub-id><pub-id pub-id-type="pmcid">PMC9236177</pub-id><pub-id pub-id-type="pmid">35501419</pub-id></mixed-citation></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>H</given-names></name></person-group><article-title>Automated feature extraction from population wearable device data identified novel loci associated with sleep and circadian rhythms</article-title><source>PLoS Genet</source><year>2020</year><volume>16</volume><issue>10</issue><fpage>e1009089</fpage><pub-id pub-id-type="pmid">33075057</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pgen.1009089</pub-id><pub-id pub-id-type="pmcid">PMC7595622</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Li X, Zhao H. Automated feature extraction from population wearable device data identified novel loci associated with sleep and circadian rhythms. PLoS Genet. 2020;16(10):e1009089.<pub-id pub-id-type="pmid">33075057</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pgen.1009089</pub-id><pub-id pub-id-type="pmcid">PMC7595622</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>F</given-names></name><name name-style="western"><surname>Hu</surname><given-names>H</given-names></name><etal/></person-group><article-title>Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets</article-title><source>Nat Genet</source><year>2016</year><volume>48</volume><issue>5</issue><fpage>481</fpage><lpage>487</lpage><pub-id pub-id-type="pmid">27019110</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ng.3538</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Zhu Z, Zhang F, Hu H, et al. Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets. Nat Genet. 2016;48(5):481&#8211;7.<pub-id pub-id-type="pmid">27019110</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ng.3538</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ochoa</surname><given-names>D</given-names></name><etal/></person-group><article-title>Open targets platform: supporting systematic drug-target identification and prioritisation</article-title><source>Nucleic Acids Res</source><year>2021</year><volume>49</volume><fpage>D1302</fpage><lpage>D1310</lpage><pub-id pub-id-type="pmid">33196847</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkaa1027</pub-id><pub-id pub-id-type="pmcid">PMC7779013</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Ochoa D, et al. Open targets platform: supporting systematic drug-target identification and prioritisation. Nucleic Acids Res. 2021;49:D1302&#8211;10.<pub-id pub-id-type="pmid">33196847</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkaa1027</pub-id><pub-id pub-id-type="pmcid">PMC7779013</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saveanu</surname><given-names>L</given-names></name><name name-style="western"><surname>Carroll</surname><given-names>O</given-names></name><name name-style="western"><surname>Lindo</surname><given-names>V</given-names></name><name name-style="western"><surname>Del Val</surname><given-names>M</given-names></name><name name-style="western"><surname>Lopez</surname><given-names>D</given-names></name><name name-style="western"><surname>Lepelletier</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Concerted peptide trimming by human ERAP1 and ERAP2 aminopeptidase complexes in the endoplasmic reticulum</article-title><source>Nat Immunol</source><year>2005</year><volume>6</volume><fpage>689</fpage><lpage>697</lpage><pub-id pub-id-type="pmid">15908954</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ni1208</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Saveanu L, Carroll O, Lindo V, Del Val M, Lopez D, Lepelletier Y, et al. Concerted peptide trimming by human ERAP1 and ERAP2 aminopeptidase complexes in the endoplasmic reticulum. Nat Immunol. 2005;6:689&#8211;97.<pub-id pub-id-type="pmid">15908954</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ni1208</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raja</surname><given-names>A</given-names></name><name name-style="western"><surname>Kuiper</surname><given-names>JJW</given-names></name></person-group><article-title>Evolutionary immuno-genetics of endoplasmic reticulum aminopeptidase II (ERAP2)</article-title><source>Genes Immun</source><year>2023</year><volume>24</volume><issue>6</issue><fpage>295</fpage><lpage>302</lpage><pub-id pub-id-type="pmid">37925533</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41435-023-00225-8</pub-id><pub-id pub-id-type="pmcid">PMC10721543</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Raja A, Kuiper JJW. Evolutionary immuno-genetics of endoplasmic reticulum aminopeptidase II (ERAP2). Genes Immun. 2023;24(6):295&#8211;302.<pub-id pub-id-type="pmid">37925533</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41435-023-00225-8</pub-id><pub-id pub-id-type="pmcid">PMC10721543</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><collab>International Genetics of Ankylosing Spondylitis Consortium (IGAS)</collab><name name-style="western"><surname>Cortes</surname><given-names>A</given-names></name><name name-style="western"><surname>Hadler</surname><given-names>J</given-names></name><etal/></person-group><article-title>Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci</article-title><source>Nat Genet</source><year>2013</year><volume>45</volume><issue>7</issue><fpage>730</fpage><lpage>738</lpage><pub-id pub-id-type="pmid">23749187</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ng.2667</pub-id><pub-id pub-id-type="pmcid">PMC3757343</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">International Genetics of Ankylosing Spondylitis Consortium (IGAS), Cortes A, Hadler J, et al. Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. Nat Genet. 2013;45(7):730&#8211;8.<pub-id pub-id-type="pmid">23749187</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ng.2667</pub-id><pub-id pub-id-type="pmcid">PMC3757343</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>JZ</given-names></name><name name-style="western"><surname>van Sommeren</surname><given-names>S</given-names></name><name name-style="western"><surname>Huang</surname><given-names>H</given-names></name><etal/></person-group><article-title>Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations</article-title><source>Nat Genet</source><year>2015</year><volume>47</volume><issue>9</issue><fpage>979</fpage><lpage>986</lpage><pub-id pub-id-type="pmid">26192919</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ng.3359</pub-id><pub-id pub-id-type="pmcid">PMC4881818</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Liu JZ, van Sommeren S, Huang H, et al. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat Genet. 2015;47(9):979&#8211;86.<pub-id pub-id-type="pmid">26192919</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ng.3359</pub-id><pub-id pub-id-type="pmcid">PMC4881818</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Castro</surname><given-names>JAL</given-names></name><name name-style="western"><surname>Stratikos</surname><given-names>E</given-names></name></person-group><article-title>Intracellular antigen processing by ERAP2: Molecular mechanism and roles in health and disease</article-title><source>Hum Immunol</source><year>2019</year><volume>80</volume><fpage>310</fpage><lpage>317</lpage><pub-id pub-id-type="pmid">30414458</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.humimm.2018.11.001</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">de Castro JAL, Stratikos E. Intracellular antigen processing by ERAP2: Molecular mechanism and roles in health and disease. Hum Immunol. 2019;80:310&#8211;7.<pub-id pub-id-type="pmid">30414458</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.humimm.2018.11.001</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klunk</surname><given-names>J</given-names></name><name name-style="western"><surname>Vilgalys</surname><given-names>TP</given-names></name><name name-style="western"><surname>Demeure</surname><given-names>CE</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>X</given-names></name><name name-style="western"><surname>Shiratori</surname><given-names>M</given-names></name><name name-style="western"><surname>Madej</surname><given-names>J</given-names></name><etal/></person-group><article-title>Evolution of immune genes is associated with the Black Death</article-title><source>Nature</source><year>2022</year><volume>611</volume><fpage>312</fpage><lpage>319</lpage><pub-id pub-id-type="pmid">36261521</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-022-05349-x</pub-id><pub-id pub-id-type="pmcid">PMC9580435</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Klunk J, Vilgalys TP, Demeure CE, Cheng X, Shiratori M, Madej J, et al. Evolution of immune genes is associated with the Black Death. Nature. 2022;611:312&#8211;9.<pub-id pub-id-type="pmid">36261521</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-022-05349-x</pub-id><pub-id pub-id-type="pmcid">PMC9580435</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hamilton</surname><given-names>F</given-names></name><name name-style="western"><surname>Mentzer</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Parks</surname><given-names>T</given-names></name><name name-style="western"><surname>Baillie</surname><given-names>JK</given-names></name><name name-style="western"><surname>Smith</surname><given-names>GD</given-names></name><name name-style="western"><surname>Ghazal</surname><given-names>P</given-names></name><etal/></person-group><article-title>Variation in ERAP2 has opposing effects on severe respiratory infection and autoimmune disease</article-title><source>Am J Hum Genet</source><year>2023</year><volume>110</volume><fpage>691</fpage><lpage>702</lpage><pub-id pub-id-type="pmid">36889308</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajhg.2023.02.008</pub-id><pub-id pub-id-type="pmcid">PMC10119032</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Hamilton F, Mentzer AJ, Parks T, Baillie JK, Smith GD, Ghazal P, et al. Variation in ERAP2 has opposing effects on severe respiratory infection and autoimmune disease. Am J Hum Genet. 2023;110:691&#8211;702.<pub-id pub-id-type="pmid">36889308</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajhg.2023.02.008</pub-id><pub-id pub-id-type="pmcid">PMC10119032</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><mixed-citation publication-type="other">Kuiper JJ, Prinz JC, Stratikos E, Ku&#347;nierczyk P, Arakawa A, Springer S, et al. EULAR studygroup MHC-I-opathies. EULAR study group on &#8216;MHC-I-opathy&#8217;: identifying disease-overarching mechanisms across disciplines and borders. Ann Rheum Dis. 2023;82:887&#8211;96.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/ard-2022-222852</pub-id><pub-id pub-id-type="pmcid">PMC10313995</pub-id><pub-id pub-id-type="pmid">36987655</pub-id></mixed-citation></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Evnouchidou</surname><given-names>I</given-names></name><name name-style="western"><surname>Papakyriakou</surname><given-names>A</given-names></name><name name-style="western"><surname>Stratikos</surname><given-names>E</given-names></name></person-group><article-title>A new role for Zn(II) aminopeptidases: antigenic peptide generation and destruction</article-title><source>Curr Pharm Des</source><year>2009</year><volume>15</volume><issue>31</issue><fpage>3656</fpage><lpage>3670</lpage><pub-id pub-id-type="pmid">19925418</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/138161209789271816</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Evnouchidou I, Papakyriakou A, Stratikos E. A new role for Zn(II) aminopeptidases: antigenic peptide generation and destruction. Curr Pharm Des. 2009;15(31):3656&#8211;70.<pub-id pub-id-type="pmid">19925418</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/138161209789271816</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>ED</given-names></name></person-group><article-title>Endoplasmic Reticulum Aminopeptidase 2, a common immunological link to adverse pregnancy outcomes and cancer clearance?</article-title><source>Placenta</source><year>2017</year><volume>56</volume><fpage>40</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1016/j.placenta.2017.03.012</pub-id><pub-id pub-id-type="pmid">28343731</pub-id><pub-id pub-id-type="pmcid">PMC5522626</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Lee ED. Endoplasmic Reticulum Aminopeptidase 2, a common immunological link to adverse pregnancy outcomes and cancer clearance? Placenta. 2017;56:40&#8211;3. 10.1016/j.placenta.2017.03.012.<pub-id pub-id-type="pmid">28343731</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.placenta.2017.03.012</pub-id><pub-id pub-id-type="pmcid">PMC5522626</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guilliams</surname><given-names>M</given-names></name><name name-style="western"><surname>Ginhoux</surname><given-names>F</given-names></name><name name-style="western"><surname>Jakubzick</surname><given-names>C</given-names></name><etal/></person-group><article-title>Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny</article-title><source>Nat Rev Immunol</source><year>2014</year><volume>14</volume><issue>8</issue><fpage>571</fpage><lpage>578</lpage><pub-id pub-id-type="pmid">25033907</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nri3712</pub-id><pub-id pub-id-type="pmcid">PMC4638219</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Guilliams M, Ginhoux F, Jakubzick C, et al. Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny. Nat Rev Immunol. 2014;14(8):571&#8211;8.<pub-id pub-id-type="pmid">25033907</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nri3712</pub-id><pub-id pub-id-type="pmcid">PMC4638219</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pudjihartono</surname><given-names>N</given-names></name><name name-style="western"><surname>Ho</surname><given-names>D</given-names></name><name name-style="western"><surname>Golovina</surname><given-names>E</given-names></name><etal/></person-group><article-title>Juvenile idiopathic arthritis-associated genetic loci exhibit spatially constrained gene regulatory effects across multiple tissues and immune cell types</article-title><source>J Autoimmun</source><year>2023</year><volume>138</volume><fpage>103046</fpage><pub-id pub-id-type="doi">10.1016/j.jaut.2023.103046</pub-id><pub-id pub-id-type="pmid">37229810</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Pudjihartono N, Ho D, Golovina E, et al. Juvenile idiopathic arthritis-associated genetic loci exhibit spatially constrained gene regulatory effects across multiple tissues and immune cell types. J Autoimmun. 2023;138:103046. 10.1016/j.jaut.2023.103046.<pub-id pub-id-type="pmid">37229810</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaut.2023.103046</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stoehr</surname><given-names>CG</given-names></name><name name-style="western"><surname>Buettner-Herold</surname><given-names>M</given-names></name><name name-style="western"><surname>Kamphausen</surname><given-names>E</given-names></name><name name-style="western"><surname>Bertz</surname><given-names>S</given-names></name><name name-style="western"><surname>Hartmann</surname><given-names>A</given-names></name><name name-style="western"><surname>Seliger</surname><given-names>B</given-names></name></person-group><article-title>Comparative expression profiling for human endoplasmic reticulum-resident aminopeptidases 1 and 2 in normal kidney versus distinct renal cell carcinoma subtypes</article-title><source>Int J Clin Exp Pathol</source><year>2013</year><volume>6</volume><issue>6</issue><fpage>998</fpage><lpage>1008</lpage><pub-id pub-id-type="pmid">23696916</pub-id><pub-id pub-id-type="pmcid">PMC3657351</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Stoehr CG, Buettner-Herold M, Kamphausen E, Bertz S, Hartmann A, Seliger B. Comparative expression profiling for human endoplasmic reticulum-resident aminopeptidases 1 and 2 in normal kidney versus distinct renal cell carcinoma subtypes. Int J Clin Exp Pathol. 2013;6(6):998&#8211;1008. Published 2013 May 15.<pub-id pub-id-type="pmid">23696916</pub-id><pub-id pub-id-type="pmcid">PMC3657351</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Corridoni</surname><given-names>D</given-names></name><name name-style="western"><surname>Arseneau</surname><given-names>KO</given-names></name><name name-style="western"><surname>Cifone</surname><given-names>MG</given-names></name><name name-style="western"><surname>Cominelli</surname><given-names>F</given-names></name></person-group><article-title>The dual role of nod-like receptors in mucosal innate immunity and chronic intestinal inflammation</article-title><source>Front Immunol</source><year>2014</year><volume>5</volume><fpage>317</fpage><pub-id pub-id-type="pmid">25071778</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2014.00317</pub-id><pub-id pub-id-type="pmcid">PMC4090755</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Corridoni D, Arseneau KO, Cifone MG, Cominelli F. The dual role of nod-like receptors in mucosal innate immunity and chronic intestinal inflammation. Front Immunol. 2014;5:317.<pub-id pub-id-type="pmid">25071778</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2014.00317</pub-id><pub-id pub-id-type="pmcid">PMC4090755</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>G</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>MH</given-names></name><name name-style="western"><surname>Kim</surname><given-names>YG</given-names></name><name name-style="western"><surname>Nu&#241;ez</surname><given-names>G</given-names></name></person-group><article-title>NOD-like receptors: role in innate immunity and inflammatory disease</article-title><source>Annu Rev Pathol</source><year>2009</year><volume>4</volume><fpage>365</fpage><lpage>398</lpage><pub-id pub-id-type="pmid">18928408</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev.pathol.4.110807.092239</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Chen G, Shaw MH, Kim YG, Nu&#241;ez G. NOD-like receptors: role in innate immunity and inflammatory disease. Annu Rev Pathol. 2009;4:365&#8211;98.<pub-id pub-id-type="pmid">18928408</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev.pathol.4.110807.092239</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>CA</given-names></name><name name-style="western"><surname>Chiang</surname><given-names>BL</given-names></name></person-group><article-title>Inflammasomes and human autoimmunity: a comprehensive review</article-title><source>J Autoimmun</source><year>2015</year><volume>61</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">26005048</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaut.2015.05.001</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Yang CA, Chiang BL. Inflammasomes and human autoimmunity: a comprehensive review. J Autoimmun. 2015;61:1&#8211;8.<pub-id pub-id-type="pmid">26005048</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaut.2015.05.001</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>JJY</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>R</given-names></name></person-group><article-title>Systemic Juvenile idiopathic arthritis</article-title><source>Pediatr Clin North Am</source><year>2018</year><volume>65</volume><issue>4</issue><fpage>691</fpage><lpage>709</lpage><pub-id pub-id-type="pmid">30031494</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pcl.2018.04.005</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Lee JJY, Schneider R. Systemic Juvenile idiopathic arthritis. Pediatr Clin North Am. 2018;65(4):691&#8211;709.<pub-id pub-id-type="pmid">30031494</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pcl.2018.04.005</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hinze</surname><given-names>CH</given-names></name><name name-style="western"><surname>Foell</surname><given-names>D</given-names></name><name name-style="western"><surname>Kessel</surname><given-names>C</given-names></name></person-group><article-title>Treatment of systemic juvenile idiopathic arthritis</article-title><source>Nat Rev Rheumatol</source><year>2023</year><volume>19</volume><issue>12</issue><fpage>778</fpage><lpage>789</lpage><pub-id pub-id-type="pmid">37923864</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41584-023-01042-z</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Hinze CH, Foell D, Kessel C. Treatment of systemic juvenile idiopathic arthritis. Nat Rev Rheumatol. 2023;19(12):778&#8211;89.<pub-id pub-id-type="pmid">37923864</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41584-023-01042-z</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Benedetti</surname><given-names>F</given-names></name><name name-style="western"><surname>Brunner</surname><given-names>HI</given-names></name><name name-style="western"><surname>Ruperto</surname><given-names>N</given-names></name><name name-style="western"><surname>Kenwright</surname><given-names>A</given-names></name><name name-style="western"><surname>Wright</surname><given-names>S</given-names></name><name name-style="western"><surname>Calvo</surname><given-names>I</given-names></name><etal/></person-group><article-title>Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis</article-title><source>N Engl J Med</source><year>2012</year><volume>367</volume><issue>25</issue><fpage>2385</fpage><lpage>2395</lpage><pub-id pub-id-type="pmid">23252525</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1112802</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">De Benedetti F, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2385&#8211;95.<pub-id pub-id-type="pmid">23252525</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1112802</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Cai</surname><given-names>H</given-names></name><name name-style="western"><surname>Sun</surname><given-names>W</given-names></name><etal/></person-group><article-title>Endoplasmic reticulum aminopeptidase 2 regulates CD4+ T cells pyroptosis in rheumatoid arthritis</article-title><source>Arthritis Res Ther</source><year>2024</year><volume>26</volume><issue>1</issue><fpage>36</fpage><pub-id pub-id-type="pmid">38273310</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13075-024-03271-3</pub-id><pub-id pub-id-type="pmcid">PMC10810225</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Zhang J, Cai H, Sun W, et al. Endoplasmic reticulum aminopeptidase 2 regulates CD4+ T cells pyroptosis in rheumatoid arthritis. Arthritis Res Ther. 2024;26(1):36.<pub-id pub-id-type="pmid">38273310</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13075-024-03271-3</pub-id><pub-id pub-id-type="pmcid">PMC10810225</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>